Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference

1. Penumbra scheduled to present at BofA Securities Health Care Conference on May 13, 2025. 2. Webcast available on company website for two weeks post-event. 3. Penumbra is a leader in thrombectomy technologies for medical conditions like ischemic stroke. 4. The company serves healthcare providers in over 100 countries to enhance patient outcomes. 5. Recent advancements focus on speed, safety, and simplicity in blood clot removal.

Corporate Developments

75

3m saved

Insight

Article

FAQ

Why Bullish?

The conference presentation can boost investor confidence and visibility for PEN, reminiscent of previous stock surges following investor events for medical companies, which often correlate with increased stock interest and market performance.

How important is it?

The announcement of a key presentation may attract attention from investors and analysts, suggesting potential growth and innovation in PEN's product pipeline, impacting market perceptions positively.

Why Short Term?

Immediate impact expected as the conference occurs soon, likely influencing trading activity leading into and following the event.

Related Companies

CAG MDT BDX

ALAMEDA, Calif., April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025.

Event: BofA Securities 2025 Health Care Conference
Date: Tuesday, May 13, 2025
Time: 6:00pm ET/3:00pm PT

A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the event.

About Penumbra

Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety, and simplicity. By pioneering these innovations, we support healthcare providers, hospitals, and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X.

Investor Relations

Penumbra, Inc.
[email protected]

SOURCE Penumbra, Inc.